Tyrphostin AG1296 100 mg | 99.68%
TargetMol
Tyrphostin AG1296 (Tyrphostin AG 1296) is an inhibitor of PDGFR with IC50 of 0.3-0.5 μM, no activity to EGFR.
More Information Supplier PageTyrphostin AG1296
Search Results
Tasquinimod 2 mg | 99.50%
TargetMol
Tasquinimod is a quinoline-3-carboxamide linomide analog with antiangiogenic and potential antineoplastic activities. Tasquinimod has been shown to decrease blood vessel density but the exact mechanism of action is not known. This agent has also been shown to augment the antineoplastic effects of docetaxel and androgen ablation in a murine model of prostate cancer involving human […]
More Information Supplier PageTasquinimod
Tasquinimod 1 mg | 99.50%
TargetMol
Tasquinimod is a quinoline-3-carboxamide linomide analog with antiangiogenic and potential antineoplastic activities. Tasquinimod has been shown to decrease blood vessel density but the exact mechanism of action is not known. This agent has also been shown to augment the antineoplastic effects of docetaxel and androgen ablation in a murine model of prostate cancer involving human […]
More Information Supplier PageTasquinimod
Sodium Picosulfate 200 mg | 99.10%
TargetMol
Sodium Picosulfate inhibits absorption of water and electrolytes, and increases their secretion.
More Information Supplier PageSodium Picosulfate
Roquinimex 10 mg | 99.65%
TargetMol
Roquinimex (Linomide) is a quinoline derivative immunostimulant which increases NK cell activity and macrophage cytotoxicity; inhibits angiogenesis and reduces the secretion of TNF alpha.
More Information Supplier PageRoquinimex
Roquinimex 5 mg | 99.65%
TargetMol
Roquinimex (Linomide) is a quinoline derivative immunostimulant which increases NK cell activity and macrophage cytotoxicity; inhibits angiogenesis and reduces the secretion of TNF alpha.
More Information Supplier PageRoquinimex
Roquinimex 2 mg | 99.65%
TargetMol
Roquinimex (Linomide) is a quinoline derivative immunostimulant which increases NK cell activity and macrophage cytotoxicity; inhibits angiogenesis and reduces the secretion of TNF alpha.
More Information Supplier PageRoquinimex
SR17018 25 mg | 99.73%
TargetMol
SR17018 is an mu-opioid-receptor (MOR) agonist, binding with GTPγS, with an EC50 of 97 nM.
More Information Supplier PageSR17018
SR17018 10 mg | 99.73%
TargetMol
SR17018 is an mu-opioid-receptor (MOR) agonist, binding with GTPγS, with an EC50 of 97 nM.
More Information Supplier PageSR17018
SR17018 5 mg | 99.73%
TargetMol
SR17018 is an mu-opioid-receptor (MOR) agonist, binding with GTPγS, with an EC50 of 97 nM.
More Information Supplier PageSR17018